Beijing Advanced Innovation Center for Genomics, Biodynamic Optical Imaging Center (BIOPIC), Peking-Tsinghua Center for Life Sciences, State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, 100871, China.
Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Sci Rep. 2018 Jan 18;8(1):1042. doi: 10.1038/s41598-018-19317-x.
Engineered nucleases in genome editing manifest diverse efficiencies at different targeted loci. There is therefore a constant need to evaluate the mutation rates at given loci. T7 endonuclease 1 (T7E1) and Surveyor mismatch cleavage assays are the most widely used methods, but they are labour and time consuming, especially when one must address multiple samples in parallel. Here, we report a surrogate system, called UDAR (Universal Donor As Reporter), to evaluate the efficiency of CRISPR/Cas9 in targeted mutagenesis. Based on the non-homologous end-joining (NHEJ)-mediated knock-in strategy, the UDAR-based assay allows us to rapidly evaluate the targeting efficiencies of sgRNAs. With one-step transfection and fluorescence-activated cell sorting (FACS) analysis, the UDAR assay can be completed on a large scale within three days. For detecting mutations generated by the CRISPR/Cas9 system, a significant positive correlation was observed between the results from the UDAR and T7E1 assays. Consistently, the UDAR assay could quantitatively assess bleomycin- or ICRF193-induced double-strand breaks (DSBs), which suggests that this novel strategy is broadly applicable to assessing the DSB-inducing capability of various agents. With the increasing impact of genome editing in biomedical studies, the UDAR method can significantly benefit the evaluation of targeted mutagenesis, especially for high-throughput purposes.
在基因组编辑中,工程化的核酸酶在不同的靶向位点表现出不同的效率。因此,需要不断评估特定基因座的突变率。T7 内切酶 1(T7E1)和 Surveyor 错配切割测定法是最广泛使用的方法,但它们既费时又费力,尤其是在必须并行处理多个样本时。在这里,我们报告了一种称为 UDAR(通用供体作为报告)的替代系统,用于评估 CRISPR/Cas9 在靶向诱变中的效率。基于非同源末端连接(NHEJ)介导的基因敲入策略,基于 UDAR 的测定法允许我们快速评估 sgRNA 的靶向效率。通过一步转染和荧光激活细胞分选(FACS)分析,可以在三天内大规模完成 UDAR 测定法。对于检测由 CRISPR/Cas9 系统产生的突变,UDAR 和 T7E1 测定法的结果之间存在显著的正相关性。一致地,UDAR 测定法可以定量评估博来霉素或 ICRF193 诱导的双链断裂(DSB),这表明这种新策略广泛适用于评估各种试剂诱导 DSB 的能力。随着基因组编辑在生物医学研究中的影响不断增加,UDAR 方法可以极大地受益于靶向诱变的评估,特别是对于高通量目的。